HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The porphyrias: advances in diagnosis and treatment.

Abstract
The inborn errors of heme biosynthesis, the porphyrias, are 8 genetically distinct metabolic disorders that can be classified as "acute hepatic," "hepatic cutaneous," and "erythropoietic cutaneous" diseases. Recent advances in understanding their pathogenesis and molecular genetic heterogeneity have led to improved diagnosis and treatment. These advances include DNA-based diagnoses for all the porphyrias, new understanding of the pathogenesis of the acute hepatic porphyrias, identification of the iron overload-induced inhibitor of hepatic uroporphyrin decarboxylase activity that causes the most common porphyria, porphyria cutanea tarda, the identification of an X-linked form of erythropoietic protoporphyria due to gain-of-function mutations in erythroid-specific 5-aminolevulinate synthase (ALAS2), and new and experimental treatments for the erythropoietic prophyrias. Knowledge of these advances is relevant for hematologists because they administer the hematin infusions to treat the acute attacks in patients with the acute hepatic porphyrias, perform the chronic phlebotomies to reduce the iron overload and clear the dermatologic lesions in porphyria cutanea tarda, and diagnose and treat the erythropoietic porphyrias, including chronic erythrocyte transfusions, bone marrow or hematopoietic stem cell transplants, and experimental pharmacologic chaperone and stem cell gene therapies for congenital erythropoietic protoporphyria. These developments are reviewed to update hematologists on the latest advances in these diverse disorders.
AuthorsManisha Balwani, Robert J Desnick
JournalHematology. American Society of Hematology. Education Program (Hematology Am Soc Hematol Educ Program) Vol. 2012 Pg. 19-27 ( 2012) ISSN: 1520-4383 [Electronic] United States
PMID23233556 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Heme
  • DNA
  • 5-Aminolevulinate Synthetase
  • ALAS2 protein, human
Topics
  • 5-Aminolevulinate Synthetase (metabolism)
  • DNA (metabolism)
  • Erythrocytes (cytology)
  • Genes, Recessive
  • Genetic Therapy (methods)
  • Hematology (methods, trends)
  • Heme (metabolism)
  • Homozygote
  • Humans
  • Metabolism, Inborn Errors
  • Models, Biological
  • Mutation
  • Phlebotomy
  • Porphyria Cutanea Tarda (diagnosis, genetics)
  • Porphyria, Erythropoietic (diagnosis, genetics)
  • Porphyrias (diagnosis, genetics, therapy)
  • Skin (pathology)
  • Stem Cells (cytology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: